News | October 14, 2024
Indian drug regulator recommends Wockhardt's Miqnaf for treatment of CABP
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
The three doses of ZyCoV-D are to be administered 28 days apart. The vaccine was given emergency use authorisation (EUA) by the Indian drug regulator on August 20
The UK’s Medicine and Healthcare products Regulatory Agency has already approved the booster dose of AstraZenenca’s Covid-19 vaccine, which is administered in India
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
Subscribe To Our Newsletter & Stay Updated
